As of 2025-06-21, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (46.40) USD. This relative valuation is based on P/E multiples. With the latest stock price at 40.65 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -214.1%.
The range of the Relative Valuation is (46.36) - (44.27) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.0x - 17.7x | 17.5x |
| Forward P/E multiples | 18.6x - 21.5x | 19.7x |
| Fair Price | (46.36) - (44.27) | (46.40) |
| Upside | -214.1% - -208.9% | -214.1% |
| Date | P/E |
| 2025-06-20 | -16.02 |
| 2025-06-18 | -16.44 |
| 2025-06-17 | -15.78 |
| 2025-06-16 | -16.53 |
| 2025-06-13 | -16.37 |
| 2025-06-12 | -16.39 |
| 2025-06-11 | -16.40 |
| 2025-06-10 | -16.48 |
| 2025-06-09 | -17.26 |
| 2025-06-06 | -17.58 |
| 2025-06-05 | -17.65 |
| 2025-06-04 | -17.07 |
| 2025-06-03 | -17.58 |
| 2025-06-02 | -17.55 |
| 2025-05-30 | -17.19 |
| 2025-05-29 | -17.39 |
| 2025-05-28 | -16.83 |
| 2025-05-27 | -16.77 |
| 2025-05-23 | -17.21 |
| 2025-05-22 | -17.20 |
| 2025-05-21 | -17.29 |
| 2025-05-20 | -17.97 |
| 2025-05-19 | -18.02 |
| 2025-05-16 | -17.49 |
| 2025-05-15 | -17.41 |
| 2025-05-14 | -17.17 |
| 2025-05-13 | -16.60 |
| 2025-05-12 | -17.69 |
| 2025-05-09 | -17.92 |
| 2025-05-08 | -18.87 |
| 2025-05-07 | -18.95 |
| 2025-05-06 | -18.59 |
| 2025-05-05 | -19.22 |
| 2025-05-02 | -18.96 |
| 2025-05-01 | -20.14 |
| 2025-04-30 | -20.78 |
| 2025-04-29 | -20.38 |
| 2025-04-28 | -19.90 |
| 2025-04-25 | -20.02 |
| 2025-04-24 | -20.00 |
| 2025-04-23 | -20.02 |
| 2025-04-22 | -19.79 |
| 2025-04-21 | -19.42 |
| 2025-04-17 | -19.72 |
| 2025-04-16 | -19.77 |
| 2025-04-15 | -19.66 |
| 2025-04-14 | -19.50 |
| 2025-04-11 | -18.59 |
| 2025-04-10 | -17.66 |
| 2025-04-09 | -18.36 |